selected publications
-
academic article
-
Scott AMAkhurst TLee F-TCiprotti MDavis IDWeickhardt AJGan HKHicks RJLee STKocovski PGuo NOh MMileshkin LWilliams SMurphy DPathmaraj KO’Keefe GJGong SJPedersen JSScott FEWheatcroft MPHudson PJ. First clinical study of a pegylated diabody 124 I-labeled PEG-AVP0458 in patients with tumor-associated glycoprotein 72 positive cancers.
Theranostics.
10:11404-11415.
2020
Full text if available -
Lau LHCliff ERSWong VWong HTorkamani NEer AWeickhardt AGrossmann M. Hypocalcaemia following denosumab in prostate cancer: A clinical review.
Clinical Endocrinology.
92:495-502.
2020
Full text if available -
Lie GWeickhardt AKearney LLam QJohn TLiew DArulananda S. Nivolumab resulting in persistently elevated troponin levels despite clinical remission of myocarditis and myositis in a patient with malignant pleural mesothelioma: case report.
Translational Lung Cancer Research.
9:360-365.
2020
Full text if available -
Schmidt AAnton AShapiro JWong SAzad AKwan ESpain LMuthusamy ATorres JParente PParnis FGoh JJoshua AMPook DGibbs PTran BWeickhardt A. Treatment outcomes for patients with metastatic castrate-resistant prostate cancer following docetaxel for hormone-sensitive disease.
Asia Pacific Journal of Clinical Oncology.
2020
Full text if available -
Emmett LMetser UBauman GHicks RJWeickhardt ADavis IDPunwani SPond GRChua SS-CHo BJohnston EPouliot FScott A. A Prospective, Multi-site, International Comparison of F-18 fluoro-methyl-choline, multi-parametric magnetic resonance and Ga-68 HBED-CC (PSMA-11) in men with High-Risk Features and Biochemical Failure after Radical Prostatectomy: Clinical Performance and Patient Outcomes.
Journal of Nuclear Medicine.
60:794-800.
2019
Full text if available -
Kramer GMYaqub MVargas HASchuit RWindhorst ADvan den Eertwegh Avan der Veldt ABergman ABurnazi ELewis JSChua SS-CStaton KBeattie BJHumm JLDavis IDWeickhardt AScott AMorris MJHoekstra OSLammertsma AA. Assessment of simplified methods for quantification of 18F-FDHT uptake in patients with metastatic castration-resistant prostate cancer.
Journal of Nuclear Medicine.
60:1221-1227.
2019
Full text if available -
Lau DKMouradov DWasenang WLuk IYScott CMWilliams DSYeung YHLimpaiboon TIatropoulos GFJenkins LJReehorst CMChionh FNikfarjam MCroagh DDhillon ASWeickhardt AJMuramatsu TSaito YTebbutt NCSieber OMMariadason JM. Genomic profiling of biliary tract cancer cell lines reveals molecular subtypes and actionable drug targets.
iScience.
21:624-637.
2019
Full text if available -
Turgeon G-AWeickhardt AAzad AASolomon BSiva S. Radiotherapy and immunotherapy: a synergistic effect in cancer care.
Medical Journal of Australia.
210:47-53.
2019
Full text if available -
Metser UChua SS-CHo BPunwani SJohnston EPouliot FTau NHawsawy AAnconina RBauman GHicks RJWeickhardt ADavis IDPond GScott ATunariu NSidhu HEmmett LM. The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of 18F-Fluoromethylcholine or 68Ga-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical Prostatectomy..
Journal of Nuclear Medicine.
60:1253-1258.
2019
Full text if available -
Ha FJSpain LDowling AKwan EMPezaro CDay DChia PLTran BPook DWeickhardt AJ. Timing of brain metastases development in metastatic renal cell cancer patients treated with targeted therapies and survival outcomes: An Australian multicenter study.
Asia Pacific Journal of Clinical Oncology.
15:e97-e102.
2019
Full text if available -
Schmidt AAzad AGoh JHarris CJoshua AMWeickhardt AKrieger L. Treatment selection for first-line metastatic renal cell carcinoma in Australia: Impact of new therapy options.
Asia Pacific Journal of Clinical Oncology.
15:3-10.
2019
Full text if available -
Anton AWong SParente PAzad AShapiro JAWeickhardt ATorres JParnis FGoh JSemira CGibbs PTran BPezaro C. Examining skeletal-related events in Australian men with castration-resistant prostate cancer (CRPC).
Annals of Oncology.
29:ix70-ix70.
2018
Full text if available -
Hamid AAHa FJDas OWeickhardt A. Communicating prognosis of patients with advanced cancer between health care providers: a tertiary cancer center review of written correspondence.
Annals of palliative medicine.
7:404-410.
2018
Full text if available -
Nebot NArkenau H-TInfante JRChandler JCWeickhardt ALickliter JDSarantopoulos JGordon MSMak GSt-Pierre ATang LMookerjee BCarson SWHayes SGrossmann KF. Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600–mutant tumours.
British Journal of Clinical Pharmacology.
84:764-775.
2018
Full text if available -
Camidge DRSequist LVJänne PAWeickhardt ADowling ESAlicea JFan JOxnard GR. Phase Ib Study of High-dose Intermittent Afatinib in Patients With Advanced Solid Tumors.
Clinical Lung Cancer.
19:e655-e665.
2018
Full text if available -
Vargas HAKramer GMScott AMWeickhardt AMeier AAParada NBeattie BJHumm JLStaton KDZanzonico PBLyashchenko SKLewis JSYaqub MSosa REvan den Eertwegh AJDavis IDAckermann UPathmaraj KSchuit RCWindhorst ADChua SWeber WALarson SMScher HILammertsma AAHoekstra OMorris MJ. Reproducibility and Repeatability of Semiquantitative 18F-Fluorodihydrotestosterone Uptake Metrics in Castration-Resistant Prostate Cancer Metastases: A Prospective Multicenter Study.
Journal of Nuclear Medicine.
59:1516-1523.
2018
Full text if available -
Mitchell ELLau PKHKhoo CLiew DLeung JLiu BRischin AFrauman AGKee DSmith KBrady BRischin DGibson AMileshkin LKlein OWeickhardt AArulananda SShackleton MMcArthur GÖstör ACebon JSolomon BBuchanan RRWicks IPLo SHicks RJSandhu S. Rheumatic immune-related adverse events secondary to anti–programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series.
European Journal of Cancer.
105:88-102.
2018
Full text if available -
Hamid AWilson KVincent ADTamjid BLee MBergin AGan CCampbell AStewart JPezaro CTran BWeickhardt AJ. Risk of febrile neutropenia and early treatment cessation in men receiving standard and dose-reduced 3-weekly docetaxel for metastatic castration-resistant prostate cancer.
Asia Pacific Journal of Clinical Oncology.
14:e399-e404.
2018
Full text if available -
Yeung YLau DKChionh FTran HTse JWTWeickhardt AJNikfarjam MScott AMTebbutt NCMariadason JM. K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines.
Molecular Oncology.
11:1130-1142.
2017
Full text if available -
Ha FJWeickhardt AJParakh SVincent ADGlassford NJWarrillow SJones D. Survival and functional outcomes of patients with metastatic solid organ cancer admitted to the intensive care unit of a tertiary centre.
Critical Care and Resuscitation.
19:159-166.
2017
-
Ackermann ULewis JSYoung KMorris MJWeickhardt ADavis IDScott AM. Fully automated synthesis of [18F]fluoro-dihydrotestosterone ([18F]FDHT) using the FlexLab module.
Journal of Labelled Compounds and Radiopharmaceuticals.
59:424-428.
2016
Full text if available -
Price TJBruhn MALee CKHardingham JETownsend ARMann KPSimes JWeickhardt AWrin JWWilson KGebski VVan Hazel GRobinson BCunningham DTebbutt NC. Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer.
British Journal of Cancer.
112:963-970.
2015
Full text if available -
Weickhardt AJWilliams DSLee CKChionh FSimes JMurone CWilson KParry MMAsadi KScott AMPunt CJANagtegaal IDPrice TJMariadason JMTebbutt NC. Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer.
British Journal of Cancer.
113:37-45.
2015
Full text if available -
Brosnan EMWeickhardt ALu XMaxon DABarón AEChonchol MCamidge DR. Drug-Induced Reduction in Estimated Glomerular Filtration Rate in Patients With ALK-Positive Non-Small Cell Lung Cancer Treated With the ALK Inhibitor Crizotinib.
Cancer.
120:664-674.
2014
Full text if available -
Aisner DLNguyen TTPaskulin DDLe ATHaney JSchulte NChionh FHardingham JMariadason JTebbutt NDoebele RCWeickhardt AJVarella-Garcia M. ROS1
and
ALK
Fusions in Colorectal Cancer, with Evidence of Intratumoral Heterogeneity for Molecular Drivers.
Molecular Cancer Research.
12:111-118.
2014
Full text if available -
Gan GNWeickhardt AScheier BDoebele RCGaspar LEKavanagh BDCamidge DR. Stereotactic Radiation Therapy can Safely and Durably Control Sites of Extra-Central Nervous System Oligoprogressive Disease in Anaplastic Lymphoma Kinase-Positive Lung Cancer Patients Receiving Crizotinib.
International Journal of Radiation: Oncology - Biology - Physics.
88:892-898.
2014
Full text if available -
Bowles DWWeickhardt AJimeno A. Afatinib for the treatment of patients with EGFR-positive non-small cell lung cancer.
Drugs of Today.
49:523-535.
2013
Full text if available -
Weickhardt AJAisner DLFranklin WAVarella-Garcia MDoebele RCCamidge DR. Diagnostic Assays for Identification of Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer.
Cancer.
119:1467-1477.
2013
Full text if available -
Price TJHardingham JELee CKTownsend ARWrin JWWilson KWeickhardt ASimes RJMurone CTebbutt NC. Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab*.
Cancer Medicine.
2:277-285.
2013
Full text if available -
Weickhardt AJDoebele RCPurcell WTBunn PAOton ABRothman MSWierman MEMok TPopat SBauman JNieva JNovello SOu SHICamidge DR. Symptomatic Reduction in Free Testosterone Levels Secondary to Crizotinib Use in Male Cancer Patients.
Cancer.
119:2383-2390.
2013
Full text if available -
Weickhardt AJScheier BBurke JMGan GLu XBunn PAAisner DLGaspar LEKavanagh BDDoebele RCCamidge DR. Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer.
Journal of Thoracic Oncology.
7:1807-1814.
2012
Full text if available -
Gan GNCamidge DRWeickhardt AJDoebele RCDzingle WScheier BKavanagh BD. Ablative Local Therapy Extends the Clinical Benefit of Crizotinib in Alk-positive Lung Cancer.
International Journal of Radiation: Oncology - Biology - Physics.
84:S67-S68.
2012
Full text if available -
Weickhardt AJRothman MSSalian-Mehta SKiseljak-Vassiliades KOton ABDoebele RCWierman MECamidge DR. Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer.
Cancer.
118:5302-5309.
2012
Full text if available -
Doebele RCLu XSumey CMaxson DAWeickhardt AJOton ABBunn PABarón AEFranklin WAAisner DLVarella-Garcia MCamidge DR. Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer.
Cancer.
118:4502-4511.
2012
Full text if available -
Weickhardt AJDoebele RCRoss Camidge D. A time to test, a time to treat.
Journal of Thoracic Disease.
4:223-225.
2012
Full text if available -
Doebele RCPilling ABAisner DLKutateladze TGLe ATWeickhardt AJKondo KLLinderman DJHeasley LEFranklin WAVarella-Garcia MCamidge DR. Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer.
Clinical Cancer Research.
18:1472-1482.
2012
Full text if available -
Weickhardt ADoebele ROton ALettieri JMaxson DReynolds MBrown AJackson MKDy GAdjei AFetterly GLu XFranklin WVarella-Garcia MHirsch FRWynes MWYoussoufian HAdjei ACamidge DR. A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients with Advanced Non-small Cell Lung Cancer.
Journal of Thoracic Oncology.
7:419-426.
2012
Full text if available -
Bowles DWWeickhardt AJDoebele RCCamidge DRJimeno A. Crizotinib for the treatment of patients with advanced non-small cell lung cancer.
Drugs of Today.
48:271-271.
2012
Full text if available -
Weickhardt AJPrice TJChong GGebski VPavlakis NJohns TGAzad ASkrinos EFluck KDobrovic ASalemi RScott AMMariadason JMTebbutt NC. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.
Journal of Clinical Oncology.
30:1505-1512.
2012
Full text if available -
Weickhardt AWells KMessersmith W. Oxaliplatin-Induced Neuropathy in Colorectal Cancer.
Journal of Oncology.
2011:1-7.
2011
Full text if available -
Weickhardt AMariadason JMJ. Weickhardt AC. Tebbutt NM. Mariadason J. Strategies for Overcoming Inherent and Acquired Resistance to EGFR Inhibitors by Targeting Downstream Effectors in the RAS/PI3K Pathway.
Current Cancer Drug Targets.
10:824-833.
2010
Full text if available -
WEICKHARDT AJOSEPH TSHEA SARHANGHELSCHI DLOWE AHAMILTON KCHONG G. Comparison of radiologically inserted arm portsversussurgically placed chest ports for chemotherapy.
Asia Pacific Journal of Clinical Oncology.
5:181-186.
2009
Full text if available
-
Scott AMAkhurst TLee F-TCiprotti MDavis IDWeickhardt AJGan HKHicks RJLee STKocovski PGuo NOh MMileshkin LWilliams SMurphy DPathmaraj KO’Keefe GJGong SJPedersen JSScott FEWheatcroft MPHudson PJ. First clinical study of a pegylated diabody 124 I-labeled PEG-AVP0458 in patients with tumor-associated glycoprotein 72 positive cancers.
Theranostics.
10:11404-11415.
2020
-
case study
-
Browning ETWeickhardt ACamidge DR. Response to crizotinib rechallenge after initial progression and intervening chemotherapy in ALK lung cancer.
Journal of Thoracic Oncology.
e21-e22.
2013
Full text if available
-
Browning ETWeickhardt ACamidge DR. Response to crizotinib rechallenge after initial progression and intervening chemotherapy in ALK lung cancer.
Journal of Thoracic Oncology.
e21-e22.
2013
-
conference paper
-
Luke JJPatel MRHamilton EPChmielowski BUlahannan SVKindler HLBahadur SWClingan PRMallesara GWeickhardt AJCurrence SXu LKaul SChen FMoore PABonvini ESumrow BBlumenschein G. A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms..
Journal of Clinical Oncology.
2020
-
Weickhardt AJForoudi FLawrentschuk NGalleta LSeegum AHerschtal ALink EMcJannett MMLiow ECHGrimison PSZhang AYPatanjali NNg SGoodwin RTang CChen CHovey EJHruby GGuminski ADDavis ID. Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: A planned interim analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502).
Journal of Clinical Oncology.
2020
-
Schmidt ALAnton AWong SSAzad AKwan EMSpain LATorres JMuthusamy AParente PParnis FGoh JCJoshua AMPook DWGibbs PTran BWeickhardt AJ. Treatment outcomes for metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) following docetaxel (D) for hormone sensitive disease.
Journal of Clinical Oncology.
2020
-
Chazan GAnton AWong SShapiro JWeickhardt AAzad AKwan ESpain LMuthusamy ATorres JParente PParnis FGoh JJoshua APook DGibbs PTran B. Beyond cabazitaxel: Late line treatments in metastatic castration resistant prostate cancer (mCRPC): A retrospective multicentre analysis.
Asia Pacific Journal of Clinical Oncology.
117-117.
2019
-
Liow EBaenziger OCorrente CLaw NAzad AShapiro JShapiro JWeickhardt ASchmidt AParnis FWong SParente PAnton APezaro CTran B. Australian Treatment Practices for Patients with Metastatic Renal Cell Carcinoma (MRCC).
Asia Pacific Journal of Clinical Oncology.
55-55.
2019
-
Cui WPhuong PGoz KCorrente CBaenziger ONDundee PZargar HAnderson PLawrentschuk NGibbs PIschia JWeickhardt AWong L-MCernelc JFox SSengupta STran B. Examining the Association between PD-L1 Expression and Clinicopathological Features and Survival Outcomes in Australian Urothelial Cancer Patients.
Asia Pacific Journal of Clinical Oncology.
45-46.
2019
-
Kelly RAnton AWong SShapiro JWeickhardt AAzad AKwan ESpain LMuthusamy ATorres JParente PParnis FGoh JJoshua APook DGibbs PTran B. Real-World Use of First-Generation Anti-androgens (FGAs): Their Influence on Patient Outcomes and Subsequent Therapies in Metastatic Castration-Resistant Prostate Cancer (mCPRC).
Asia Pacific Journal of Clinical Oncology.
51-51.
2019
-
Zhang AYToner GCLawrence NJStockler MRMartin AJFord KStevanovic AGWyld DWalpole ETTroon SHanning FJMallesara GWeickhardt AJBirtle AJDavis IDGrimison PS. P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for adult and pediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs)..
Journal of Clinical Oncology.
TPS539-TPS539.
2019
Full text if available -
Metser UChua SHo NBBPunwani SJohnston EPouliot FTau NHawsawy AAnconina RBauman GHicks RWeickhardt ADavis IPond GScott AEmmett L. The contribution of multiparametric pelvic and whole body MR to the interpretation of F-18-fluoromethylcholine(FCH) or Ga-68-HBED-CC PSMA-11 (PSMA) PET/CT in the detection of pelvic recurrence or distant metastases in patients with biochemical failure following radical prostatectomy..
Journal of Nuclear Medicine.
2019
-
Hong DSSchoffski PCalvo ASarantopoulos JOchoa De Olza MCarvajal RDPrawira AKyi CEsaki TAkerley WLDe Braud FGHui RZhang TSoo RAMaur MWeickhardt AJRoy Chowdhury NSabatos-Peyton CKwak ELTan DS-W. Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies..
Journal of Clinical Oncology.
3012-3012.
2018
Full text if available -
Anton AParente PAzad AWeickhardt AWong SShapiro JTorres JParnis FSemira CGibbs PTran BPezaro C. Use of Bone-Modifying Agents in Australian Men with Castration-Resistant Prostate Cancer (CRPC).
Asia Pacific Journal of Clinical Oncology.
32-32.
2018
-
Nayar NLawrence NJStockler MRMartin AJYip SWong NYeung AFriedlander MMazhar DPashankar FQuinn DIMcDermott RWalker RWinstanley MHanning FJWeickhardt AJStevanovic AGDavis IDToner GCGrimison PS. P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs)..
Journal of Clinical Oncology.
TPS574-TPS574.
2018
Full text if available -
Bauman GSMetser UScott APouliot FWeickhardt ADavis IHicks RPunwani SChua SEmmett L. A Prospective Study of F-18 Fluoro-methyl-choline (FCH) And Ga-68 HBED-CC- (PSMA) in Men being Considered for Salvage Radiation Treatment for Biochemical Failure Post Radical Prostatectomy.
International Journal of Radiation: Oncology - Biology - Physics.
S162-S162.
2018
Full text if available -
Emmett LMetser UBauman GHicks RPouliot FDavis IChua SWeickhardt APunwani SHo BJohnston EScott A. A prospective, multinational comparison of multi-parametric and whole body magnetic resonance imaging (mp-MRI and WB-MRI) F-18 fluoro-methyl-choline (FCH) and Ga-68 HBED-CC-(PSMA) in high risk men being considered for salvage radiation treatment for biochemical failure post radical prostatectomy: Detection rates, management impact and treatment response.
Journal of Nuclear Medicine.
2018
-
Weickhardt AJForoudi FSengupta SGalletta LHerschtal AGrimison PSPatanjali NNg STang CGoodwin RHovey EJJarvis TChen CSandhu SKTai KHLawrentschuk NDavis ID. Pembrolizumab and chemoradiotherapy for muscle invasive bladder cancer: The ANZUP 1502 PCR-MIB trial.
Journal of Clinical Oncology.
TPS531-TPS531.
2018
Full text if available -
Vargas AKramer GScott AWeickhardt AMeier AParada NBeattie BHumm JStaton KZanzonico PLyashchenko SLewis JYaqub MSosa RWeber WVan den Eertwegh ASchuit RWindhorst AChua SLarson SScher HLammertsma AHoekstra OMorris M. Reproducibility and repeatability of quantitative F-18-fluorodihydrotestosterone (FDHT) uptake metrics in castration resistant prostate cancer metastases: a prospective multi-center study..
Journal of Nuclear Medicine.
2018
-
Wong NNayar NLawrence NStockler MMartin AYip SYeung AFriedlander MMazhar DPashankar FQuinn DWalker RWinstanley MWeickhardt AHanning FStevanovic ADavis IToner GGrimison P. P3BEP (ANZUP 1302): An International Randomised Phase III Trial of Accelerated Versus Standard BEP Chemotherapy for Adult and Pediatric Male and Female Patients With Intermediate and Poor-Risk Metastatic Germ Cell Tumours (GCTS).
Asia Pacific Journal of Clinical Oncology.
168-168.
2017
-
Banks PSan Leong HRyland GBeshay VTran BToner GMurphy DFox SWeickhardt APezaro CThorne HGoode DFellowes ASandhu S. DNA repair gene defects in Australian men with metastatic castration-resistant prostate cancer (mCRPC).
BJU International.
8-8.
2017
-
Hamid AHa FDas OWeickhardt A. Documenting Goals of Care and Prognosis of Advanced Cancer Patients: A Tertiary Cancer Center Review of Internal and External Correspondence.
Asia Pacific Journal of Clinical Oncology.
47-47.
2017
-
Ha FJJones DParakh SVincent ADGlassford NJWarrillow SWeickhardt AJ. Metastatic Solid Organ Cancer Patients Admitted to the Intensive Care Unit: Survival and Functional Outcomes.
Asia Pacific Journal of Clinical Oncology.
42-42.
2017
-
Weickhardt ALau DLavis AGarms MMariadason J. ACQUIRED RESISTANCE TO THE FIBROBLAST GROWTH FACTOR RECEPTOR ( FGFR) INHIBITOR BGJ398 IN FGFR3 DRIVEN BLADDER CANCER IS OVERCOME BY CO-TARGETING THE RAPIDLY INDUCED PAXL OR PERBB3 PATHWAYS.
Asia Pacific Journal of Clinical Oncology.
63-63.
2017
-
Banks PLeong HSRyland GBeshay VTran BToner GMurphy DFox SWeickhardt APezaro CThorne HGoode DFellowes ASandhu S. DNA REPAIR GENE DEFECTS IN AUSTRALIAN MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC).
Asia Pacific Journal of Clinical Oncology.
58-58.
2017
-
Grimison PSLawrence NJStockler MRMartin AJYip SWong NYeung AFriedlander MMazhar DPashankar FQuinn DIWalker RWinstanley MHanning FJWeickhardt AJStevanovic AGDavis IDToner GC. P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs)..
Journal of Clinical Oncology.
TPS4592-TPS4592.
2017
Full text if available -
Ha FJWeickhardt AJParakh SGlassford NJWarrillow SJones D. Survival and functional outcomes of patients with metastatic solid organ cancer admitted to the intensive care unit of a general tertiary centre.
Annals of Oncology.
vi517-vi517.
2016
Full text if available -
Hamid AWilson KPezaro CLee MTran BBergin AGan CTamjid BCampbell AStewart JVincent AWeickhardt A. PREDICTORS OF FEBRILE NEUTROPAENIA AND EARLY TREATMENT CESSATION DUE TO TOXICITY IN MEN RECEIVING Q3 WEEKLY DOCETAXEL FOR METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC).
Asia Pacific Journal of Clinical Oncology.
35-35.
2016
-
Nebot NArkenau HTInfante JRChandler JCWeickhardt ALickliter JDSarantopoulos JGordon MSSt-Pierre ATang LMookerjee BCarson SWGrossmann KF. Evaluation of the effect of dabrafenib on QTc interval in patients with BRAF V600–mutant tumors..
Journal of Clinical Oncology.
e14119-e14119.
2016
Full text if available -
Weickhardt AJForoudi FSengupta SGrimison PPatanjali NLeslie SNg STang CGoodwin RHovey EJarvis TChen CHerschtal AGalletta LSandhu STai K-HLawrentschuk NDavis I. Pembrolizumab with ChemoRadiotherapy for Muscle Invasive Bladder Cancer: the ANZUP PCR-MIB trial.
Annals of Oncology.
2016
Full text if available -
Lawrence NToner GMartin AStockler MYeung AWong NThomson DGebski VYip SKing MFriedlander MQuinn DTan THChan HHanning FWeickhardt AJeffery MStevanovic AHovey EWyld DDavis IGrimison P. A RANDOMISED PHASE 3 TRIAL OF ACCELERATED VERSUS STANDARD BEP CHEMOTHERAPY FOR PATIENTS WITH INTERMEDIATE AND POOR-RISK METASTATIC GERM CELL TUMOURS: THE P3BEP TRIAL (ANZUP 1302).
Asia Pacific Journal of Clinical Oncology.
146-147.
2015
-
Scott AMAkhurst TLee FCiprotti MDavis IWeickhardt AGan HKocovski PGuo NMurphy DHicks RLee SO'Keefe GGong SHudson P. Phase I Safety and Biodistribution Study of 124I-PEG-AVP0458 Diabody in Patients with TAG-72 Positive Ovarian and Prostate Cancer.
European Journal of Nuclear Medicine and Molecular Imaging.
S122-S122.
2015
-
Spain LDowling AKwan EPezaro CDai DChia PTran BPook DWeickhardt A. 2586 Pattern of presentation of brain metastases (BM) in metastatic renal cell cancer (mRCC) patients (pts) treated with targeted therapies (TT): Implications for screening practice.
European Journal of Cancer.
S507-S507.
2015
Full text if available -
Scott AMAkhurst TLee F-TCiprotti MDavis IWeickhardt AGan HKocovski PGuo NMileshkin LWilliams SMurphy DHicks RPathmaraj KLee STO'Keefe GGong SOh MWheatcroft MHudson PJ. Phase I safety and biodistribution study of 124I-PEG-AVP0458 diabody in patients with TAG-72 positive ovarian and prostate cancer.
Cancer Research.
2015
Full text if available -
Willson KJVincent ATamjid BStewart JWeickhardt A. EFFICACY AND TOXICITY OF 60 MG/M-2 DOCETAXEL COMPARED TO 75 MG/M-2 DOCETAXEL FOR THE TREATMENT OF METASTATIC CASTRATE RESISTANT PROSTATE CANCER.
Asia Pacific Journal of Clinical Oncology.
42-42.
2015
-
Scott AMAkhurst TLee F-TCiprotti MDavis IWeickhardt AGan HKocovski PGuo NMileshkin LWilliams SMurphy DHicks RPathmaraj KLee STO'Keefe GJGong STochon-Danguy HPoniger SOh MWheatcroft MHudson PJ. PHASE I SAFETY AND BIODISTRIBUTION STUDY OF 124I-PEG-AVP0458 DIABODY IN PATIENTS WITH TAG-72 POSITIVE OVARIAN AND PROSTATE CANCER.
Internal Medicine Journal.
11-11.
2015
-
Scott AAkhurst TLee F-TCiprotti MDavis IWeickhardt AHicks RLee STOh MHudson P. Phase I Safety and Biodistribution Study of I-124-PEG-AVP0458 Diabody in Patients with TAG-72 Positive Ovarian and Prostate Cancer.
Journal of Nuclear Medicine.
2015
-
Weickhardt AChionh FJMGebski VChueh ACAl-Obaidi SJWelckhardt AJLee CWilliams DSMurone CWilson KScott AMSimes JPrice TJMariadason JMTebbutt NC. Single nucleotide polymorphisms (SNPs) in vascular endothelial growth factor (VEGF) family genes as predictive or prognostic biomarkers in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of the phase III MAX Inter study..
Journal of Clinical Oncology.
2014
Full text if available -
Sengupta SLiew MSPrithviraj PTafreshi AStewart JWeickhardt AAzad ABolton D. Stage I seminoma - treatment choices and outcomes at a single tertiary referral institution.
BJU International.
68-69.
2014
-
Price TJBruhn MLee CHardingham JTownsend ARMann KSimes JWeickhardt AJWrin JWilson KGebski VRobinson BAVan Hazel GACunningham DTebbutt NC. Correlation of PI3KCAand extended RAS gene mutation status with outcomes from the phase III AGITG MAX involving capecitabine (C) alone or in combination with bevacizumab (B) with or without mitomycin C (M) in advanced colorectal cancer (CRC)..
Journal of Clinical Oncology.
2014
Full text if available -
Spain LStewart JCampbell ALim AJoon DLWeickhardt A. MANAGEMENT OF BRAIN METASTASES IN PATIENTS WITH RENAL CELL CARCINOMA IN THE ERA OF TYROSINE KINASE INHIBITORS AND STEREOTACTIC RADIOTHERAPY.
Asia Pacific Journal of Clinical Oncology.
42-42.
2014
-
Weickhardt AJNguyen TTPaskulin DDLe ATAisner DSchulte NChionh FJMMariadason JTebbutt NCDoebele RCVarella-Garcia M. ALK and ROS1 gene rearrangements detected in colorectal cancer (CRC) by fluorescence in situ hybridization (FISH).
Journal of Clinical Oncology.
2013
-
Gan GNCamidge DRWeickhardt AJDoebele RCDzingle WScheier BKavanagh BD. Ablative Local Therapy Extends The Clinical Benefit Of Crizotinib In Alk-positive Lung Cancer.
Journal of Thoracic Oncology.
S211-S211.
2012
-
Price THardingham JLee CTownsend AWrin JWilson KWeickhardt ASimes RJMunroe CTebbutt N. PTEN AND ADVANCED COLORECTAL CANCER (CRC): ANALYSIS FROM THE PHASE III AGITG MAX TRIAL OF CAPECITABINE ALONE OR IN COMBINATION WITH BEVACIZUMAB +/- MITOMYCIN C.
Annals of Oncology.
182-182.
2012
-
Price TJHardingham JLee CWrin JTownsend ARWilson KWeickhardt AJSimes JMurone CTebbutt NC. Analysis of PTEN in patients with advanced colorectal cancer (CRC) receiving capecitabine alone or in combination with bevacizumab with or without mitomycin C in the phase III AGITG MAX trial.
Journal of Clinical Oncology.
2012
-
Doebele RCAisner DLLe ATBerge EMPilling ABKutateladze TGWeickhardt AJFranklin WAVarella-Garcia MCamidge DR. Analysis of resistance mechanisms to ALK kinase inhibitors in ALK plus NSCLC patients..
Journal of Clinical Oncology.
2012
-
Weickhardt AJScheier BBurke JMGan GDoebele RCBunn PAGaspar LEKavanagh BDCamidge DR. Continuation of EGFR/ALK inhibition after local therapy of oligoprogressive disease in EGFR mutant (Mt) and ALK plus non-small cell lung cancer (NSCLC).
Journal of Clinical Oncology.
2012
-
Weickhardt AJDoebele RCOton ABDy GLettieri JMaxson DAReynolds MJackson MKBrown AAdjei AFetterly GJAdjei AACamidge DR. A PHASE I/II STUDY OF ERLOTINIB IN COMBINATION WITH THE ANTI-INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR (IGF-1R) MONOCLONAL ANTIBODY IMC-A12 (CIXUTUMUMAB) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)..
Journal of Thoracic Oncology.
S606-S606.
2011
-
Weickhardt AJWilliams DLee CSimes JMurone CWilson KCummins MAsadi KPrice TJMariadason JTebbutt NC. Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): Analysis of the phase III MAX study..
Journal of Clinical Oncology.
2011
-
Price TJHardingham JELee CKWeickhardt ATownsend ARWrin JWChua AShivasami ACummins MMMurone CTebbutt NC. Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer.
Journal of Clinical Oncology.
2675-2682.
2011
Full text if available -
Price TJHardingham JLee CWeickhardt ATownsend AWrin JWShivasami ACummins MMurone CTebbutt N. IMPACT OF KRAS AND BRAF GENE MUTATION STATUS ON OUTCOMES FROM THE PHASE III AGITG MAX TRIAL OF CAPECITABINE (C) ALONE OR IN COMBINATION WITH BEVACIZUMAB (B) +/- MITOMYCIN C (M) IN ADVANCED COLORECTAL CANCER (CRC).
Annals of Oncology.
198-198.
2010
-
Weickhardt AJPrice TJPavlakis NSkrinos EDobrovic ASalemi RScott AMMariadason JChong GTebbutt NC. DUX study: A phase II study of evaluating dual targeting of the EGFR using the combination of cetuximab and erlotinib in patients with chemotherapy refractory metastatic colorectal cancer..
Journal of Clinical Oncology.
3533-3533.
2010
Full text if available
-
Luke JJPatel MRHamilton EPChmielowski BUlahannan SVKindler HLBahadur SWClingan PRMallesara GWeickhardt AJCurrence SXu LKaul SChen FMoore PABonvini ESumrow BBlumenschein G. A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms..
Journal of Clinical Oncology.
2020
-
conference poster
-
Phuong PCui WGoz KCorrente CBaenziger OWong SDundee PZargar HAnderson PLawrentschuk NGibbs PWeickhardt AWong L-MSengupta STran B. Muscle invasive (MIBC) and metastatic (mBC) urothelial cancer: Modern treatment practices and clinical outcomes in Victoria.
Asia Pacific Journal of Clinical Oncology.
120-121.
2019
-
Phuong PCui WGoz KCorrente CBaenziger OWong SDundee PZargar HAnderson PLawrentschuk NGibbs PWeickhardt AWong L-MSengupta STran B. Muscle invasive (MIBC) and metastatic (mBC) urothelial cancer: Modern treatment practices and clinical outcomes in Victoria.
Asia Pacific Journal of Clinical Oncology.
120-121.
2019
-
letter
-
Warrillow SMoran JWeickhardt A. Advanced Dementia.
New England Journal of Medicine.
1276-1276.
2015
Full text if available -
Warrillow SMoran JWeickhardt A. Advanced dementia.
New England Journal of Medicine.
1276-1276.
2015
Full text if available
-
Warrillow SMoran JWeickhardt A. Advanced Dementia.
New England Journal of Medicine.
1276-1276.
2015
-
other publication
-
Weickhardt AJWilliams DLee CSimes JMurone CWilson KCummins MAsadi KPrice TJMariadason JTebbutt NCAustralasian GI Trials Group. Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): Analysis of the phase III MAX study..
Journal of Clinical Oncology.
3531.
2011
-
Weickhardt AJWilliams DLee CSimes JMurone CWilson KCummins MAsadi KPrice TJMariadason JTebbutt NCAustralasian GI Trials Group. Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): Analysis of the phase III MAX study..
Journal of Clinical Oncology.
3531.
2011
-
abstract
-
Hodgson-Garms MMariadason JWeickhardt A. Mechanisms of acquired resistance to the fibroblast growth factor receptor (FGFR) inhibitor BGJ398 in FGFR driven bladder cancer.
Annals of Oncology.
vi540-vi540.
2016
Full text if available -
Gong SJO'Keefe GJLee STAkhurst TLee FTDavis IWeickhardt AGan HPathmeraj KHicks RJHudson PJScott AM. DOSIMETRY OF I-124-PEG-AVP0458 DIABODY IN PATIENTS WITH TAG-72 POSITIVE OVARIAN OR PROSTATE CANCER.
Internal Medicine Journal.
40-41.
2015
-
Hodgson-Garms MMariadason JWeickhardt A. Mechanisms of acquired resistance to the fibroblast growth factor receptor (FGFR) inhibitor BGJ398 in FGFR driven bladder cancer.
Annals of Oncology.
vi540-vi540.
2016